Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC

Scientists assessed the preclinical efficacy of BI-4732, a novel fourth-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, using patient-derived preclinical models reflecting various clinical scenarios.